Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial.
ESMO open, cilt.7, sa.2, ss.100410, 2022 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 7 Sayı: 2
- Basım Tarihi: 2022
- Doi Numarası: 10.1016/j.esmoop.2022.100410
- Dergi Adı: ESMO open
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE, Directory of Open Access Journals
- Sayfa Sayıları: ss.100410
- Anahtar Kelimeler: immunotherapy, radiation therapy, chemotherapy, surgery, multimodality therapy, RANDOMIZED CONTROLLED-TRIAL, PHASE-III, PREOPERATIVE CHEMOTHERAPY, INDUCTION CHEMOTHERAPY, SURGICAL RESECTION, RADIOTHERAPY, N2, SURGERY
- Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
- İstanbul Üniversitesi-Cerrahpaşa Adresli: Hayır
Özet
Background: The phase III PACIFIC trial (NCT02125461) established consolidation durvalumab as standard of care for patients with unresectable, stage III non-small-cell lung cancer (NSCLC) and no disease progression following chemoradiotherapy (CRT). In some cases, patients with stage IIIA-N2 NSCLC are considered operable, but the relative benefit of surgery is unclear. We report a post hoc, exploratory analysis of clinical outcomes in the PACIFIC trial, in patients with or without stage IIIA-N2 NSCLC.